Globalization, accompanied by increasing levels of international travel and trade, climate change, altered human behavior and demographics, is leading to the emergence of manifold viral diseases, many of which are highly pathogenic and hence are considered of great public and animal health importance to the global populace [1]. An excellent, if devastating, example of this is represented by the filovirus family, to which Ebolavirus and Marburgvirus belong. To undertake basic virological research and novel therapeutic development, filoviruses require expert handling and manipulation by highly trained staff within expensive CL-4 facilities not readily available to the virology research community [2]. In order to circumvent the enhanced biosafety requirement, the develop ment of nonpatho genic, replication-defective pseudotyped vectors, developed historically for gene therapy applications, is an effective and established solution to permit the study of many facets of filovirus biology and virus therapeutics in a low containment CL-1/2 laboratory [3]. Ebola virus glycoprotein (GP) pseudotypes constructed with murine leukemia virus cores were first described in 1998 and have been used since then in a broad range of studies [4]. In order to be able to respond in a timely and effective manner to future filovirus outbreaks, a library of pseudotyped vectors bearing the GP of filo viruses of major public and animal health importance should be prioritized. These pseudotype viruses can be readily used for sero-surveillance, mAb/antiviral screening, vaccine immunogenicity studies and for tropism/pathogenicity studies as soon as the nucleotide sequence of the GP is online. Such a collection has been instigated by Edward Wright’s group at the University of Westminster and includes to date, all five Ebolavirus species including the Makona variant (Guinea, 2014) implicated in the current outbreak [5]. These pseudotypes are currently being utilized as surrogate antigens in virus neutralization assays as part of immunogenicity studies of the vaccine ChAd3 EBOZ at the Jenner Institute (University of Oxford, UK) [6]. Pseudotypes of Zaire Ebolavirus (Mayinga), Bundibugyo Ebolavirus (2008 isolate) and Marburg virus (Lake Victoria